MCID: PTH002
MIFTS: 52

Pathological Gambling

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

MalaCards integrated aliases for Pathological Gambling:

Name: Pathological Gambling 12 15
Compulsive Gambling 12 43
Gambling, Pathological 73
Gambling 44

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD10 33 F63.0
ICD9CM 35 312.31
MeSH 44 D005715
NCIt 50 C94335
UMLS 73 C0030662

Summaries for Pathological Gambling

MedlinePlus : 43 Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet. Most people who gamble don't have a problem, but some lose control of their gambling. Signs of problem gambling include Always thinking about gambling Lying about gambling Spending work or family time gambling Feeling bad after you gamble, but not quitting Gambling with money you need for other things If you have concerns about your gambling, ask for help. Your health care provider can work with you to find the treatment that's best for you. NIH: National Institutes of Health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to impulse control disorder and alexithymia. An important gene associated with Pathological Gambling is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Topiramate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 30.2 DRD2 DRD3 DRD4
2 alexithymia 30.2 DRD2 SLC6A4
3 gilles de la tourette syndrome 30.0 DRD2 DRD4 SLC6A3
4 eating disorder 29.8 DRD2 SLC6A3 SLC6A4
5 kleptomania 29.7 MAOA SLC6A4
6 alcohol abuse 29.3 DRD2 DRD3 DRD4 SLC6A4
7 cocaine dependence 29.3 DRD2 DRD3 SLC6A3 SLC6A4
8 depression 29.3 HTR2A MAOA SLC6A4
9 anxiety 29.1 HTR2A MAOA SLC6A4
10 bulimia nervosa 28.9 HTR2A MAOA SLC6A4
11 tobacco addiction 28.7 DRD2 HTR2A MAOA SLC6A3
12 schizoaffective disorder 28.7 DRD2 DRD3 HTR2A SLC6A4
13 restless legs syndrome 27.6 DRD2 DRD3 MAOA MAOB SLC6A3
14 substance abuse 27.6 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
15 substance dependence 27.5 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
16 antisocial personality disorder 27.1 DRD2 MAOA MAOB SLC6A3 SLC6A4
17 disease of mental health 26.3 DRD2 DRD3 DRD4 HTR2A MAOA SLC6A3
18 obsessive-compulsive disorder 26.2 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
19 mood disorder 25.9 DRD2 DRD3 DRD4 HTR2A MAOA MAOB
20 personality disorder 25.5 DRD2 DRD3 DRD4 HTR2A MAOA MAOB
21 bipolar disorder 25.5 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
22 parkinson disease, late-onset 24.9 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
23 alcohol dependence 24.6 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
24 schizophrenia 24.5 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
25 gambling, pathologic 11.3
26 novelty seeking personality trait 11.0
27 polysubstance abuse 10.5 DRD2 DRD3
28 heroin dependence 10.5 DRD2 DRD4
29 schizophrenia 5 10.4 DRD3 HTR2A
30 striatonigral degeneration 10.4 DRD2 SLC6A3
31 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
32 delusional disorder 10.3 DRD2 DRD3 DRD4
33 premature ejaculation 10.2 SLC6A3 SLC6A4
34 drug-induced mental disorder 10.2 DRD2 HTR2A
35 drug psychosis 10.2 DRD2 HTR2A
36 separation anxiety disorder 10.2 DRD4 SLC6A3
37 alzheimer disease 5 10.2 HTR2A SLC6A4
38 aging 10.1
39 psychosexual disorder 10.1 HTR2A SLC6A4
40 movement disease 10.1 DRD2 DRD3 SLC6A3
41 tardive dyskinesia 10.0 DRD2 DRD3 HTR2A
42 orofacial cleft 10.0 DRD2 DRD4 SLC6A3
43 opiate dependence 10.0 DRD2 DRD3 SLC6A4
44 phobic disorder 10.0 MAOA SLC6A4
45 drug dependence 10.0 DRD2 DRD3 SLC6A4
46 fibromyalgia 10.0 HTR2A SLC6A4
47 frontotemporal dementia 10.0
48 dementia 10.0
49 frontotemporal dementia with parkinsonism-17 10.0
50 alcohol-induced mental disorder 9.9 DRD2 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

GenomeRNAi Phenotypes related to Pathological Gambling according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA

MGI Mouse Phenotypes related to Pathological Gambling:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 HTR2A MAOA MAOB SLC6A3 SLC6A4 DRD1
2 homeostasis/metabolism MP:0005376 9.76 MAOA MAOB SLC6A3 SLC6A4 DRD1 DRD2
3 muscle MP:0005369 9.35 HTR2A SLC6A3 SLC6A4 DRD1 DRD2
4 nervous system MP:0003631 9.23 MAOA MAOB SLC6A3 SLC6A4 DRD1 DRD2

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 16590-41-3 5360515
5
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
6
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
7
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 59868 119570
8
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
9 Anticonvulsants Phase 4,Phase 2
10 Anti-Obesity Agents Phase 4,Phase 2
11 Neuroprotective Agents Phase 4,Phase 2
12 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Central Nervous System Stimulants Phase 4,Phase 2
14 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Dopamine Uptake Inhibitors Phase 4,Phase 2,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
18 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
19 Narcotics Phase 4,Phase 2,Phase 3,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2
22 Dopamine agonists Phase 4,Phase 3,Phase 2
23
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
24
Carbidopa Approved Phase 3 28860-95-9 34359 38101
25
Levodopa Approved Phase 3 59-92-7 6047
26 Antiemetics Phase 3,Phase 2
27 Antipsychotic Agents Phase 3,Phase 2
28 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
29 Gastrointestinal Agents Phase 3,Phase 2
30 Psychotropic Drugs Phase 3,Phase 2,Not Applicable
31 Serotonin Agents Phase 3,Phase 2
32 Serotonin Uptake Inhibitors Phase 3,Phase 2
33 Tranquilizing Agents Phase 3,Phase 2
34 Adjuvants, Immunologic Phase 3
35 Antiparkinson Agents Phase 3,Phase 2,Not Applicable
36 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
37 Carbidopa, levodopa drug combination Phase 3
38 Antioxidants Phase 3,Phase 2,Phase 1
39
Serotonin Investigational, Nutraceutical Phase 3,Phase 2 50-67-9 5202
40
Coal tar Approved Phase 2 8007-45-2
41
Memantine Approved, Investigational Phase 2 19982-08-2 4054
42
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
43
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
44
Fluphenazine Approved Phase 2 69-23-8 3372
45
Haloperidol Approved Phase 2 52-86-8 3559
46
Naloxone Approved, Vet_approved Phase 2 465-65-6 5284596
47
Acetylcysteine Approved, Investigational Phase 2,Phase 1 616-91-1 12035
48
Nicotine Approved Phase 2 54-11-5 942 89594
49
Sertraline Approved Phase 2 79617-96-2 68617
50 Ecopipam Investigational Phase 2 112108-01-7

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
2 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
3 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
4 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
5 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Completed NCT01733199 Phase 4
6 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
7 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
8 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
9 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
10 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
11 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
12 Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects Completed NCT00360568 Phase 3 Levodopa-carbidopa intestinal gel
13 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease Completed NCT00335153 Phase 3 Levodopa-carbidopa intestinal gel
14 Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients Completed NCT00479401 Phase 3 Pramipexol Extended Release;Pramipexol Immediate Release;Placebo
15 Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD Completed NCT00577460 Phase 3 Pramipexole;Placebo
16 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
17 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
18 Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
19 Memantine Treatment Study of Pathological Gambling Completed NCT00585169 Phase 2 Memantine Hydrochloride
20 Tolcapone Treatment of Pathological Gambling Completed NCT00927563 Phase 2 Tolcapone
21 Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Completed NCT01215357 Phase 2 Ecopipam
22 Cognitive Behavioral Therapy for Pathological Gambling Completed NCT00337753 Phase 2
23 Cognitive Behavioral Treatments for Pathological Gambling Completed NCT00618462 Phase 2
24 A Pilot SMART Design for Pathological Gamblers Completed NCT00685724 Phase 2
25 D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
26 Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
27 Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
28 Indicated Prevention With At-Risk Gamblers Completed NCT00078273 Phase 2
29 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Completed NCT00967005 Phase 2 N Acetyl Cysteine
30 Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease Completed NCT01806896 Phase 2 PF-02545920;Placebo;PF-02545920;Placebo
31 The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Completed NCT00464737 Phase 2 Rotigotine;Rotigotine
32 Milk Thistle in Pathological Gambling Recruiting NCT02337634 Phase 2 Placebo;Milk Thistle
33 Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder Enrolling by invitation NCT03430180 Phase 2 Naloxone hydrochloride;Placebo
34 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Not yet recruiting NCT02934919 Phase 2 Nalmefene
35 A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease Not yet recruiting NCT03436953 Phase 2 CX-8998;Placebo
36 Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1 Terminated NCT00249431 Phase 2 Sertraline
37 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
38 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Completed NCT00273702 Phase 1 N-Acetyl Cysteine
39 Cognitive Behavioral Therapy for Treatment of Pathological Gambling Completed NCT00158314 Phase 1
40 Cognitive-Behavioral Treatment of Gambling Completed NCT00118391 Phase 1
41 The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers Unknown status NCT02491996 Not Applicable
42 Effectiveness of Therapy Treatment Unknown status NCT01596478 Not Applicable
43 Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders. Unknown status NCT00360321
44 Screening for Excessive Gambling Behaviors on the Internet Unknown status NCT02415296
45 A Prospective Clinical Study of a Cohort of Pathological or "at Risk" Gamblers Seeking Treatment Unknown status NCT01248767
46 Effects of Internet-based Treatment of Pathological Gambling Completed NCT01381250 Not Applicable
47 Impulsivity in Pathological Gambling Completed NCT00580567
48 Bupropion in the Treatment of Pathological Gambling Completed NCT00055393 Not Applicable Bupropion;Placebo
49 Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling Completed NCT00326807 Not Applicable Naltrexone
50 Cognitive-Motivational Behavior Therapy for Pathological Gamblers Completed NCT01135264 Not Applicable

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

41
Testes, Brain, Cortex, Subthalamic Nucleus, Prefrontal Cortex, Pituitary, Amygdala

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 595)
# Title Authors Year
1
The efficacy of Motivational Intervention and Cognitive-Behavioral Therapy for Pathological Gambling. ( 29353301 )
2018
2
Personality biomarkers of pathological gambling: A machine learning study. ( 29080669 )
2018
3
The Economic Burden of Pathological Gambling and Co-occurring Mental Health and Substance Use Disorders. ( 29068825 )
2018
4
In Search of Executive Impairment in Pathological Gambling: A Neuropsychological Study on Non-treatment Seeking Gamblers. ( 29455442 )
2018
5
Decision-Making Under Risk, but Not Under Ambiguity, Predicts Pathological Gambling in Discrete Types of Abstinent Substance Users. ( 29922190 )
2018
6
Pathological Gambling in Parkinson's Disease: autonomic measures and impaired decision-making. ( 29888425 )
2018
7
Problem and Pathological Gambling in Schizophrenia: Exploring Links with Substance Use and Impulsivity. ( 29453588 )
2018
8
Explaining the relation between pathological gambling and depression: Rumination as an underlying common cause. ( 29846083 )
2018
9
Pathological Gambling among Italian Nursing Students. ( 29579529 )
2018
10
Prevalence of pathological gambling in patients with alcohol dependence syndrome attending a tertiary care center in South India. ( 28483101 )
2017
11
Relationship between pathological gambling, alexithymia, and gambling type. ( 28211964 )
2017
12
Pathological gambling. ( 28381496 )
2017
13
Pathological Gambling and Motor Impulsivity: A Systematic Review with Meta-Analysis. ( 28255940 )
2017
14
Comorbid pathological gambling, mental health, and substance use disorders: Health-care services provision by clinician specialty. ( 28856904 )
2017
15
Reduced loss aversion in pathological gambling and alcohol dependence is associated with differential alterations in amygdala and prefrontal functioning. ( 29176580 )
2017
16
Personality disorders and pathological gambling. ( 27798487 )
2017
17
A prospective follow-up study of younger and older subjects with pathological gambling. ( 28645075 )
2017
18
Health Outcomes in Individuals with Problem and Pathological Gambling: An Analysis of the 2014 North Carolina Behavioral Risk Factor Survey System (BRFSS). ( 28864873 )
2017
19
Serotonin transporter density in binge eating disorder and pathological gambling: A PET study with [<sup>11</sup>C]MADAM. ( 29032922 )
2017
20
Post-traumatic stress symptoms in pathological gambling: Potential evidence of anti-reward processes. ( 28274137 )
2017
21
Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. ( 28696131 )
2017
22
The Experience of Couples in the Process of Treatment of Pathological Gambling: Couple vs. Individual Therapy. ( 29416520 )
2017
23
Who Seeks Treatment When Medicine Opens the Door to Pathological Gambling Patients-Psychiatric Comorbidity and Heavy Predominance of Online Gambling. ( 29238309 )
2017
24
Opioid receptor antagonists in the treatment of pathological gambling. ( 28983886 )
2017
25
Identifying Environmental and Social Factors Predisposing to Pathological Gambling Combining Standard Logistic Regression and Logic Learning Machine. ( 28255941 )
2017
26
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
27
A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. ( 26339899 )
2016
28
Cognitive distortions and ADHD in pathological gambling: A national longitudinal case-control cohort study. ( 27774813 )
2016
29
Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault? ( 27288799 )
2016
30
Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? ( 27623191 )
2016
31
Genome-wide association study of pathological gambling. ( 27315593 )
2016
32
Effects of High Frequency Repeated Transcranial Magnetic Stimulation and Continuous Theta Burst Stimulation on Gambling Reinforcement, Delay Discounting, and Stroop Interference in Men with Pathological Gambling. ( 27350401 )
2016
33
Predictability in Pathological Gambling? Applying the Duplication of Purchase Law to the Understanding of Cross-Purchases Between Regular and Pathological Gamblers. ( 27328818 )
2016
34
Pathological gambling: a behavioral addiction. ( 27717269 )
2016
35
Pathological gambling: a review of the neurobiological evidence relevant for its classification as an addictive disorder. ( 26935000 )
2016
36
Frontal cortex gray matter volume alterations in pathological gambling occur independently from substance use disorder. ( 26771165 )
2016
37
Intergenerational Childhood Maltreatment in Persons with DSM-IV Pathological Gambling and Their First-Degree Relatives. ( 26749583 )
2016
38
A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling. ( 27194378 )
2016
39
Development and validation of the Gambling Follow-up Scale, Self-Report version: an outcome measure in the treatment of pathological gambling. ( 27828667 )
2016
40
Impulsivity, implicit attitudes and explicit cognitions, and alcohol dependence as predictors of pathological gambling. ( 27614152 )
2016
41
Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. ( 27882998 )
2016
42
The association between pathological gambling and suicidality in treatment-seeking pathological gamblers in South Africa. ( 26855985 )
2016
43
Pathological Gambling and Associated Drug and Alcohol Abuse, Emotion Regulation, and Anxious-Depressive Symptomatology. ( 27348555 )
2016
44
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. ( 26658263 )
2016
45
Piribedil and pathological gambling in six parkinsonian patients. ( 25742580 )
2015
46
Heterogeneity of Loss Aversion in Pathological Gambling. ( 26711104 )
2015
47
Pathological Gambling Due to Aripiprazole: Two Cases. ( 27617507 )
2015
48
The relationship of DSM-IV pathological gambling to compulsive buying and other possible spectrum disorders: Results from the Iowa PG family study. ( 25660732 )
2015
49
The Role of Metacognition in Pathological Gambling: A Mediation Model. ( 25600034 )
2015
50
Correction: Increased Functional Connectivity between Prefrontal Cortex and Reward System in Pathological Gambling. ( 26196675 )
2015

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 DRD1 DRD2 DRD3 DRD4
2
Show member pathways
12.57 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
3 12.13 DRD1 DRD2 DRD3 DRD4
4
Show member pathways
11.98 DRD1 DRD2 DRD4
6 11.96 HTR2A MAOA SLC6A4
7 11.71 DRD3 DRD4 HTR2A
8
Show member pathways
11.69 DRD2 DRD3 DRD4
9 11.68 HTR2A MAOA MAOB SLC6A4
10 11.62 DRD1 DRD2 HTR2A
11
Show member pathways
11.42 DRD1 DRD2 MAOA MAOB SLC6A3
12
Show member pathways
11.32 MAOA MAOB
13
Show member pathways
11.27 MAOA SLC6A3 SLC6A4
14
Show member pathways
11.13 MAOA MAOB
15 11.1 MAOB SLC6A3
16
Show member pathways
11.08 DRD1 DRD2 DRD3 DRD4 HTR2A
17 11.06 HTR2A MAOA SLC6A4
18
Show member pathways
11 MAOA SLC6A3 SLC6A4
19 10.89 DRD1 DRD2 DRD3
20
Show member pathways
10.73 MAOA MAOB
21 10.69 MAOA MAOB
22
Show member pathways
10.65 MAOA MAOB

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.81 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
2 integral component of membrane GO:0016021 9.61 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
3 non-motile cilium GO:0097730 9.26 DRD1 DRD2
4 integral component of plasma membrane GO:0005887 9.17 DRD1 DRD2 DRD3 DRD4 HTR2A SLC6A3

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.86 DRD2 DRD3 MAOB SLC6A3
2 response to toxic substance GO:0009636 9.85 DRD2 MAOB SLC6A4
3 cellular calcium ion homeostasis GO:0006874 9.83 DRD3 DRD4 HTR2A
4 locomotory behavior GO:0007626 9.83 DRD1 DRD2 DRD3 SLC6A3
5 memory GO:0007613 9.81 DRD1 HTR2A SLC6A4
6 social behavior GO:0035176 9.8 DRD3 DRD4 SLC6A4
7 visual learning GO:0008542 9.79 DRD1 DRD2 DRD3
8 arachidonic acid secretion GO:0050482 9.76 DRD2 DRD3 DRD4
9 regulation of dopamine secretion GO:0014059 9.75 DRD2 DRD3 HTR2A
10 temperature homeostasis GO:0001659 9.74 DRD1 DRD2 HTR2A
11 response to cocaine GO:0042220 9.73 DRD1 DRD2 DRD3 SLC6A3
12 neurotransmitter transport GO:0006836 9.72 SLC6A3 SLC6A4
13 feeding behavior GO:0007631 9.72 DRD1 DRD2
14 response to nicotine GO:0035094 9.72 DRD2 SLC6A3
15 release of sequestered calcium ion into cytosol GO:0051209 9.72 DRD2 HTR2A
16 positive regulation of cytokinesis GO:0032467 9.72 DRD2 DRD3
17 synaptic transmission, dopaminergic GO:0001963 9.72 DRD1 DRD2 DRD3
18 positive regulation of multicellular organism growth GO:0040018 9.71 DRD2 SLC6A3
19 response to morphine GO:0043278 9.71 DRD2 DRD3
20 associative learning GO:0008306 9.71 DRD1 DRD2
21 adult walking behavior GO:0007628 9.71 DRD1 DRD2
22 behavioral fear response GO:0001662 9.71 DRD1 DRD4
23 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3 DRD4
24 response to amphetamine GO:0001975 9.71 DRD1 DRD2 DRD3 DRD4
25 negative regulation of blood pressure GO:0045776 9.7 DRD2 DRD3
26 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
27 behavioral response to ethanol GO:0048149 9.7 DRD2 DRD4
28 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 DRD2 HTR2A
29 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
30 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A3 SLC6A4
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD3 DRD4
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.68 DRD1 DRD2
33 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD2 DRD4
34 grooming behavior GO:0007625 9.68 DRD1 DRD2
35 striatum development GO:0021756 9.68 DRD1 DRD2
36 G-protein coupled receptor internalization GO:0002031 9.67 DRD2 DRD3
37 neurotransmitter catabolic process GO:0042135 9.67 MAOA MAOB
38 regulation of dopamine metabolic process GO:0042053 9.67 DRD1 DRD4 SLC6A3
39 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.66 DRD1 DRD3
40 peristalsis GO:0030432 9.66 DRD1 DRD2
41 monoamine transport GO:0015844 9.65 SLC6A3 SLC6A4
42 adenohypophysis development GO:0021984 9.65 DRD2 SLC6A3
43 dopamine catabolic process GO:0042420 9.65 MAOA MAOB SLC6A3
44 dopamine transport GO:0015872 9.64 DRD1 SLC6A3
45 dopamine uptake involved in synaptic transmission GO:0051583 9.63 SLC6A3 SLC6A4
46 cerebral cortex GABAergic interneuron migration GO:0021853 9.63 DRD1 DRD2
47 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.63 DRD1 DRD2 DRD3
48 dopamine receptor signaling pathway GO:0007212 9.62 DRD1 DRD2 DRD3 DRD4
49 acid secretion GO:0046717 9.61 DRD2 DRD3
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 DRD1 DRD2 DRD3 DRD4 HTR2A
2 obsolete signal transducer activity GO:0004871 9.72 DRD1 DRD2 DRD3 DRD4 HTR2A
3 drug binding GO:0008144 9.55 DRD2 DRD3 DRD4 HTR2A SLC6A3
4 G-protein alpha-subunit binding GO:0001965 9.49 DRD1 HTR2A
5 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
6 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
8 primary amine oxidase activity GO:0008131 9.4 MAOA MAOB
9 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
10 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD1 DRD2 DRD3 DRD4
11 dopamine binding GO:0035240 9.02 DRD1 DRD2 DRD3 DRD4 SLC6A3

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....